Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753881 | 0.86 | NLRP3 (0.51) | NLRP3TLR7TLR8KDM4EALDH1A1 | |
| SCHEMBL30345870 | 0.84 | NLRP3 (0.50) | NLRP3TLR7TLR8 | |
| SCHEMBL483316 | 0.84 | NLRP3 (0.50) | NLRP3TLR7TLR8 | |
| SCHEMBL3865747 | 0.83 | NLRP3 (0.54) | NLRP3TLR7TLR8 | |
| SCHEMBL3865082 | 0.80 | NLRP3 (0.54) | NLRP3TLR7TLR8 | |
| SCHEMBL3865444 | 0.76 | TLR7 (0.48) | NLRP3TLR7TLR8 | |
| SCHEMBL26862646 | 0.75 | NLRP3 (0.61) | NLRP3TLR7TLR8 | |
| SCHEMBL30345871 | 0.74 | KDM4E (0.45) | NLRP3TLR7KDM4EALDH1A1GLA | |
| SCHEMBL483361 | 0.74 | KDM4E (0.45) | NLRP3TLR7KDM4EALDH1A1GLA | |
| SCHEMBL13645844 | 0.74 | NLRP3 (0.47) | NLRP3TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | NLRP3 4669/4885TLR7 194/4885TLR8 494/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | NLRP3 2981/4885TLR7 27/4885TLR8 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.